TABLE 4.

Univariate regression models for individual components of TRM score (entire study cohort)

	Non-relapse mortality	Relapse	Relapse-free survival	Overall survival
Age at HCT	1.03 (1.02–1.04), P<0.001	1.01 (1.00–1.02), P=0.038	1.02 (1.01–1.02), P<0.001	1.02 (1.01–1.02), P<0.001
ECOG performance status
0 (n=152)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)
1 (n=646)	2.36 (1.44–3.87), P<0.001	1.48 (1.06–2.08), P=0.022	1.76 (1.33–2.32), P<0.001	1.84 (1.37–2.47), P<0.001
2–3 (n=63)	8.79 (4.78–16.18), P<0.001	3.80 (2.36–6.12), P<0.001	5.24 (3.62–7.60), P<0.001	5.85 (3.98–8.60), P<0.001
Type of AML
De novo (n=628)	1 (Reference)	1 (Reference)	1 (Reference)	1 (Reference)
Secondary (n=233)	1.40 (1.03–1.91), P=0.033	1.13 (0.88–1.47), P=0.34	1.23 (1.01–1.50), P=0.037	1.22 (0.99–1.51), P=0.056
WBC at HCT	0.94 (0.88–1.01), P=0.10	0.92 (0.87–0.97), P=0.0026	0.93 (0.89–0.97), P<0.001	0.93 (0.89–0.98), P=0.0025
Platelet count at HCT	1.00 (0.99–1.00), P=0.01	1.00 (1.00–1.00), P=0.08	1.00 (1.00–1.00), P=0.0031	1.00 (1.00–1.00), P=0.0037
Serum creatinine at HCT	2.71 (1.63–4.51), P<0.001	0.81 (0.50–1.32), P=0.40	1.37 (0.96–1.95), P=0.08	1.57 (1.09–2.26), P=0.016
Serum albumin at HCT	0.39 (0.26–0.58), P<0.001	0.71 (0.51–0.98), P=0.035	0.56 (0.43–0.72), P<0.001	0.55 (0.42–0.71), P<0.001

Results are presented as hazard radio (95% confidence interval), and P-value; Abbreviations: ECOG, Eastern Cooperative Oncology Group; HCT, hematopoietic cell transplantation; WBC, total white blood cell count.